<DOC>
	<DOCNO>NCT02024607</DOCNO>
	<brief_summary>This open label , multi-center , Phase 1/2 dose escalation study BBI608 administer combination either FOLFOX6 without bevacizumab , CAPOX , FOLFIRI without bevacizumab , regorafenib , irinotecan .</brief_summary>
	<brief_title>A Study BBI608 Combination With Standard Chemotherapies Adult Patients With Advanced Gastrointestinal Cancer</brief_title>
	<detailed_description>This open label , multi-center , Phase 1/2 dose escalation study BBI608 administer combination either FOLFOX6 without bevacizumab , CAPOX , FOLFIRI without bevacizumab , regorafenib , irinotecan . A study cycle consist daily continuous oral administration BBI608 four week ( 28 day ) combination FOLFOX6 without bevacizumab , CAPOX , FOLFIRI without bevacizumab , regorafenib , irinotecan .</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Signed write informed consent 2 . A histologically confirm solid tumor gastrointestinal tract include 1 . Advanced unresectable , metastatic recurrent colorectal carcinoma ( CRC ) treatment FOLFOX6 without bevacizumab , FOLFIRI without bevacizumab , CAPOX , regorafenib would acceptable determined Investigator . FOLFIRIrefractory patient CRC enrol FOLFIRI study arm must fail treatment one FOLFIRI without bevacizumab regimen unresectable metastatic disease . Treatment failure define progression disease ( clinical radiologic ) treatment FOLFIRI without bevacizumab &lt; 3 month last dose treatment FOLFIRI without bevacizumab . Patients CRC enrol regorafenib arm study previously receive least two previous line therapy advance colorectal cancer , previously receive treatment fluoropyrimidine , oxaliplatin , irinotecan . Patients Kras wild type tumor enrol regorafenib arm also previously receive either cetuximab panitumumab . 2 . Hepatocellular carcinoma treatment FOLFOX6 CAPOX would acceptable determined Investigator . 3 . Pancreatic adenocarcinoma treatment FOLFOX6 , CAPOX , FOLFIRI , irinotecan would acceptable determined Investigator . 4 . Cholangiocarcinoma treatment FOLFOX6 CAPOX would acceptable determined Investigator . 5 . Gastric , GEJ esophageal adenocarcinoma treatment FOLFOX6 , CAPOX , FOLFIRI , irinotecan would acceptable determined Investigator . 3 . Patients may treatment naïve , may receive standard chemotherapy ; include regimen contain fluoropyrimidine , oxaliplatin , irinotecan , regorafenib , bevacizumab . 4 . ≥18 year age . 5 . Karnofsky performance status score ≥70 % . 6 . Male female patient childproducing potential agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose . 7 . Females childbearing potential negative serum pregnancy test . 8 . AST level ≤2.5 x ULN ALT ≤ 2.5 × ULN . For patient liver metastasis , AST ≤3.5 x ULN , AST ≤3.5 x ULN may enrol agree upon investigator medical monitor sponsor . 9 . Hemoglobin ≥10 g/dl . 10 . Total bilirubin level ≤1.5 × ULN . 11 . Creatinine ≤1.5 x ULN creatinine clearance &gt; 60 mL/min/1.73 m^2 patient creatinine level institutional normal ( determined CockcroftGault equation ) . 12 . Absolute neutrophil count ≥ 1.5 x 10^9/L . 13 . Platelets ≥100 x 10^9/L . 14 . Life expectancy estimate ≥3 month . 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI608 . 2 . Major surgery within 4 week prior first dose . 3 . Any known untreated brain metastasis . Treated subject must stable 4 week completion treatment , image documentation require . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . 4 . Pregnant breastfeeding . 5 . Significant gastrointestinal disorder ( ) would , opinion Principal Investigator , prevent absorption orally available agent 6 . Unable unwilling swallow BBI608 capsule daily . 7 . Prior treatment BBI608 . 8 . Uncontrolled intercurrent illness 9 . For patient treated regimen contain 5fluorouracil/leucovorin : 1 . Known hypersensitivity 5fluorouracil/leucovorin 2 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 10 . For patient treated regimen contain capecitabine : 1 . Known hypersensitivity capecitabine 2 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 3 . Significant gastrointestinal disorder ( ) would , opinion Principal Investigator , prevent absorption orally available agent 11 . For patient treated regimen contain oxaliplatin : 1 . Neurosensory neuropathy ≥ grade 2 baseline 2 . Known hypersensitivity oxaliplatin platinum contain compound 12 . For patient treated regimen contain irinotecan : 1 . Known hypersensitivity irinotecan 2 . Abnormal glucuronidation bilirubin 13 . For patient treated regimen contain bevacizumab : 1 . Current uncontrolled hypertension well prior history hypertensive crisis hypertensive encephalopathy 2 . History cardiac disease : congestive heart failure ( CHF ) &gt; NYHA Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; unevaluated new onset angina within 3 month unstable angina cardiac arrhythmia require antiarrhythmic therapy 3 . History arterial thrombotic embolic event ( within 6 month prior study entry ) 4 . Significant vascular disease 5 . Evidence bleed diathesis clinically significant coagulopathy 6 . Major surgical procedure within 28 day , anticipation need major surgical procedure course study well minor surgical procedure within 7 day prior study enrollment 7 . Proteinuria screen demonstrated urinalysis proteinuria ≥ 2+ . 8 . History abdominal fistula , gastrointestinal perforation , peptic ulcer , intraabdominal abscess within 6 month 9 . Ongoing serious , nonhealing wound , ulcer , bone fracture 10 . Known hypersensitivity component bevacizumab 11 . History reversible posterior leukoencephalopathy syndrome ( RPLS ) 14 . For patient treated regimen contain regorafenib : 1 . History cardiac disease : congestive heart failure ( CHF ) &gt; NYHA Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; unevaluated new onset angina within 3 month unstable angina cardiac arrhythmia require antiarrhythmic therapy 2 . Current uncontrolled hypertension 3 . Interstitial lung disease ongoing sign symptoms time screen 4 . History HIV infection chronic hepatitis B C 5 . Active clinically serious infection 6 . History arterial embolic event ( within 6 month prior study entry ) 7 . Liver cirrhosis ≥ ChildPugh class B uncontrolled ascites 8 . History RPLS 9 . Ongoing serious , nonhealing wound , ulcer , bone fracture 10 . Evidence bleed diathesis clinically significant coagulopathy 11 . Renal failure require hemo peritoneal dialysis 12 . Persistent proteinuria CTCAE grade 3 ( &gt; 3.5g/24 hour ) 13 . Significant gastrointestinal disorder ( ) would , opinion Principal Investigator , prevent absorption orally available agent 14 . Known hypersensitivity regorafenib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>